DEF: Concentra Group Holdings Parent Inc. Sets 2026 Annual Meeting Agenda

Concentra Group Holdings Parent, Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, executive compensation, and auditor ratification, alongside detailed corporate governance and compensation disclosures.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on April 30, 2026, at 11:00 a.m. CDT, with a record date for voting of March 5, 2026.
• Key proposals include the election of Vipin Gopal, William K. Newton, and Marc R. Watkins, MD as Class II directors for three-year terms, a non-binding advisory vote on named executive officer (NEO) compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026.
• The Board of Directors recommends voting FOR all director nominees, FOR the executive compensation, and FOR the auditor ratification.
• The company's executive compensation program is designed to attract and retain talent, provide competitive compensation, and align management interests with long-term equity owners, with 78.4% stockholder approval at the 2025 Annual Meeting.
• Stock ownership guidelines require the CEO and Chairman to own 3.0x their base salary, the President and CFO 3.0x, and other NEOs 1.5x, while non-employee directors must own 5x their annual cash compensation.
• The company maintains anti-hedging and insider trading policies, along with a compensation recovery (clawback) policy for incentive-based compensation in the event of an accounting restatement.
• For fiscal year 2025, the CEO's total annual compensation was $7,399,513, resulting in a pay ratio of 140:1 to the median employee ($53,008), or 120:1 ($61,794) excluding per diem employees.
• Key financial performance measures for executive compensation in 2025 were Adjusted EBITDA and Earnings per Share.
• Audit fees paid to PricewaterhouseCoopers LLP increased from $1,107,000 in 2024 to $2,186,000 in 2025, partly due to acquisitions.
• The company completed an initial public offering (IPO) on July 26, 2024, raising $499.7 million in net proceeds, and a spin-off from Select Medical Corporation on November 25, 2024.
• A disclosed related party transaction involves the CEO's son serving as Senior Vice President of Strategy & Finance, with an annual base salary of $315,000, a target annual bonus of $157,500, and a 2025 restricted stock award of 37,500 shares (fair value $726,000).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While it demonstrates strong corporate governance and risk management, particularly in cybersecurity, the reported Total Shareholder Return underperformance relative to the initial investment and industry index, coupled with a high CEO pay ratio, presents areas of concern for investors.

Positives

• The Board of Directors comprises a majority of independent directors (five out of seven), and all members of the Nominating, Governance and Sustainability, Human Capital and Compensation, and Audit and Compliance Committees are independent.
• An independent Lead Director, Daniel J. Thomas, was designated in 2025 to enhance independent oversight and serve as a liaison between the Chairman and independent directors.
• The company has separated the roles of Chairman (Robert A. Ortenzio) and Chief Executive Officer (William K. Newton) to allow the CEO to focus on strategic priorities and ensure effective independent oversight.
• A robust corporate governance framework is in place, including a Code of Conduct and a Code of Ethics for Senior Financial Officers, supported by a compliance program, reporting system, and disciplinary measures.
• The company operates a strong cybersecurity program aligned with the NIST Cybersecurity Framework, undergoing annual external assessments and HIPAA Security Risk Assessment Tool compliance, with no material cybersecurity breaches in the past three fiscal years.
• The Audit and Compliance Committee chairman, Daniel J. Thomas, qualifies as an audit committee financial expert, meeting SEC and NYSE standards.
• The Human Capital and Compensation Committee, composed of members with extensive healthcare industry experience, actively works to align executive compensation with financial performance and long-term shareholder value.
• Stockholders demonstrated strong support for the executive compensation program, with approximately 78.4% of votes cast in favor at the 2025 Annual Meeting.
• Comprehensive stock ownership guidelines for NEOs and non-employee directors, along with anti-hedging and insider trading policies, aim to strengthen alignment between management and shareholder interests.
• A compensation recovery policy is in place, allowing the company to claw back incentive-based compensation in the event of an accounting restatement, reinforcing accountability.

Negatives

• The company's Total Shareholder Return (TSR) for 2025 was $88.86 and for 2024 was $88.24, both indicating a decline from an initial $100 investment made on July 25, 2024.
• The company's TSR underperformed the S&P Health Care Services Select Industry Index (SPSIHP) TSR for both 2024 and 2025, suggesting a relative decline in shareholder value compared to its peer group.
• Audit fees paid to PricewaterhouseCoopers LLP significantly increased from $1,107,000 in 2024 to $2,186,000 in 2025, although partly attributed to acquisitions.
• The CEO to median employee pay ratio of 140:1 (or 120:1 excluding per diem employees) is high, which could be a point of concern for some stakeholders, despite additional context provided by the company.

Risks

• Regulatory risk, credit risk, liquidity risk, and risk from adverse fluctuations in interest rates.
• Reputational risk.
• Cybersecurity risk, including business disruption, fraud, extortion, reputational harm, violations of laws and regulations, litigation, and harm to employees, patients, customers, and business partners.
• The scope and impact of any future cybersecurity incident cannot be predicted, despite current safeguards and insurance.
• Potential for accounting restatement triggering the compensation recovery policy.
• Tax liabilities and obligations related to the Separation and Distribution from Select Medical Corporation, including indemnification for tax-free status failures.
• Restrictions on certain actions (share issuances, business combinations, sales of assets) for two years post-Distribution to preserve tax-free status, potentially limiting strategic flexibility.
• Joint and several liability with Select to the IRS for consolidated U.S. federal income taxes for periods when the company was part of the Select group.

Future Outlook

The company's executive compensation program is designed to attract and retain individuals, motivate them to achieve financial and operational goals, and align their interests with long-term equity owners. The Human Capital and Compensation Committee will continue to monitor and consider stockholder advisory votes on executive compensation for future programs. Final voting results for the 2026 Annual Meeting will be published in a Current Report on Form 8-K within four business days. The Audit and Compliance Committee has selected PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026, subject to stockholder ratification. The company will adhere to financial reporting covenants as long as Select is required to consolidate its results or account for its investment. Certain strategic actions are restricted for two years post-Distribution to preserve the tax-free nature of the Separation.

Management Comments

• "We consider your vote important and encourage you to vote as soon as possible."
• "The Board of Directors recommends a vote FOR the election of Vipin Gopal, William K. Newton, and Marc R. Watkins, MD as Class II directors, FOR the approval of, on a non-binding advisory basis, the compensation of our named executive officers, and FOR ratification of the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the year ending December 31, 2026."
• "Our Board has determined that having a leadership structure composed of a Chairman partnered with a strong Lead Director is in the best interests of our stockholders at this time and supports effective risk oversight."
• "As a newly public company, the Board felt it was appropriate to separate the roles of Chairman and Chief Executive Officer to give Mr. Newton an opportunity to focus on the day-to-day management of the business and on executing our strategic priorities, while allowing Mr. Ortenzio to focus on leading the Board and, with Mr. Thomas, to facilitate the Boards independent oversight."
• "The Human Capital and Compensation Committee considered this result [78.4% approval of executive compensation] as one factor in its evaluation of the Companys executive compensation program and determined that the strong level of shareholder support indicated endorsement of the Committees compensation philosophy and decisions."
• "The Company believes that these guidelines [stock ownership] ensure that NEOs hold a sufficient amount of the Companys common stock to further strengthen the long-term link between the results achieved for the Companys stockholders and the compensation provided to the NEOs."
• "The Company believes that a more accurate disclosure would exclude per diem employees who have no set work schedule and work only on an as-needed basis, which may be a few times a year."
• "Because a significant amount of our Chief Executive Officers compensation for 2025 was in the form of equity compensation, and only a very small number of our employees receive equity compensation, we thought it would be helpful to our stockholders to see how the above ratios are impacted by excluding equity compensation."

Industry Context

StockSavvy.ai notes that the healthcare services industry is dynamic, with increasing focus on corporate governance, executive compensation transparency, and robust cybersecurity measures. The company's detailed disclosures on these fronts, including its adherence to the NIST Cybersecurity Framework and annual external assessments, reflect a proactive approach in a sector highly susceptible to data breaches and regulatory scrutiny. The separation from Select Medical Corporation and subsequent IPO position the company as an independent entity navigating these industry trends. The underperformance in Total Shareholder Return compared to the S&P Health Care Services Select Industry Index suggests that while internal governance is strong, market perception or operational performance may not be fully capitalizing on broader industry tailwinds or is facing specific competitive pressures.

Comparison to Industry Standards

• The company's Total Shareholder Return (TSR) of $88.86 for 2025 and $88.24 for 2024, based on an initial $100 investment, indicates underperformance compared to the S&P Health Care Services Select Industry Index (SPSIHP) TSR, which is implied to be higher given the context of the graph. This suggests the company's stock has not kept pace with its industry peers since its IPO.
• The CEO to median employee pay ratio of 140:1 (or 120:1 excluding per diem employees) is higher than the average for many S&P 500 companies, which often range from 100:1 to 300:1, but can vary significantly by industry and company size. The company's additional disclosure excluding equity compensation (57:1 or 49:1) provides a more nuanced view, acknowledging that equity awards heavily influence the ratio, a common factor in executive compensation across industries.
• The company's robust cybersecurity program, structured around the NIST Cybersecurity Framework and including annual external assessments and HIPAA Security Risk Assessment Tool compliance, aligns with best practices for data-sensitive industries like healthcare, demonstrating a commitment to security comparable to leading healthcare providers and technology firms.

Corporate Governance

Related Party Transactions

• The company entered into a Separation Agreement with Select Medical Corporation (SMC) on July 26, 2024, governing the spin-off, with most intercompany arrangements terminating upon Separation.
• Net proceeds of $499.7 million from the IPO were paid to SMC to repay related party debt.
• A Tax Matters Agreement was entered into with Select, governing tax liabilities, attributes, returns, and contests, including indemnification for tax-free status failures and joint and several liability for U.S. federal income taxes for prior periods.
• An Employee Matters Agreement with SMC addressed employment, compensation, and benefits matters, including employee transfers, vesting of Select restricted stock awards, and establishment of new health/welfare and 401(k) plans.
• A Transition Services Agreement with SMC provides specified services (HR, finance, IT, real estate, compliance, legal, risk management, government affairs, distribution, tax) for up to 24 months post-Separation, with negotiated costs.
• Robert A. Ortenzio (Chairman) and Daniel J. Thomas (Lead Director) both serve on the Board of Directors of Select, with Mr. Ortenzio also being Executive Chairman of Select and owning 11.3% of Select common stock as of February 28, 2026.
• The son of William K. Newton (CEO and director) serves as Senior Vice President of Strategy & Finance, with an annual base salary of $315,000, a $157,500 target annual bonus, and received 37,500 restricted shares (grant date fair value $726,000) in 2025, and an annual bonus of approximately $317,500 on February 27, 2026.

Stakeholder Impact

• Shareholders: Directly impacted by voting on governance matters and executive compensation. The reported underperformance in Total Shareholder Return relative to the industry index may raise concerns, while stock ownership guidelines aim to align interests.
• Employees: Affected by executive compensation policies, human capital strategy, and benefit plans. The median employee pay ratio highlights compensation disparity, and the Employee Matters Agreement addressed benefit transitions post-Separation.
• Customers/Patients: The Quality of Care and Patient Safety Committee's oversight and robust cybersecurity measures indicate a focus on delivering quality medical care and protecting patient data.
• Suppliers/Creditors: The Separation Agreement and Tax Matters Agreement define responsibilities and indemnifications that could influence relationships with creditors and suppliers, particularly regarding historical liabilities and tax obligations.
• Regulatory Authorities: The company's adherence to SEC, NYSE, and HIPAA regulations, along with other legal and regulatory requirements, demonstrates compliance efforts.

Next Steps

• Stockholders are to vote on Class II director elections, executive compensation, and auditor ratification at the Annual Meeting on April 30, 2026.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K within four business days following the meeting.
• The Human Capital and Compensation Committee will consider the stockholder advisory vote on executive compensation when evaluating future compensation programs.
• The Audit and Compliance Committee may reconsider the appointment of PricewaterhouseCoopers LLP if not ratified by stockholders.
• The Nominating, Governance and Sustainability Committee will review each director's continuation on the Board of Directors every three years.
• The company will continue to comply with covenants relating to financial reporting for as long as Select is required to consolidate its results or account for its investment in the company under the equity method.
• The company is restricted from certain actions (share issuances, business combinations, sales of assets) for two years after the Distribution date to preserve the tax-free status of the Separation and Distribution, unless specific conditions are met.

Key Dates

Recommendation

The filing primarily concerns routine corporate governance matters for an upcoming annual meeting, including director elections and advisory votes on executive compensation and auditor ratification. While it provides detailed financial metrics for executive compensation and historical TSR, it does not contain new operational or financial results that would significantly alter the company's valuation or immediate prospects. The reported TSR underperformance relative to the industry index and the initial investment is a negative, but it's historical data already reflected in the market. The strong corporate governance framework and risk management practices are positive but expected for a public company. The related party transactions are disclosed but do not appear to be new or immediately impactful. Therefore, a 'hold' recommendation is appropriate as there's no new information compelling a 'buy' or 'sell' decision based solely on this proxy statement.

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, SEC Filing, Shareholder Vote, Cybersecurity, Risk Management, Financial Reporting, Stock Ownership Guidelines, Related Party Transactions, IPO, Spin-off, Healthcare Industry, EBITDA, Earnings per Share, Total Shareholder Return